Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. | Semantic Scholar
Raji-hPD-1 cells | ADCC targets | InvivoGen
Frontiers | The Role of PD-1 in Acute and Chronic Infection
PD-1 in T-cell activation, exhaustion, and effector function. (A) T... | Download Scientific Diagram
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape | Molecular Cancer | Full Text
Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer - ScienceDirect
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors | Molecular Cancer | Full Text
PD-1-high TILs: a predictive biomarker for ICB in lung cancer
PD-1/PD-L1, What a Powerful Immune Checkpoint-CUSABIO
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer: Molecular Therapy
Cancers | Free Full-Text | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Biomarkers of response to PD-1 pathway blockade | British Journal of Cancer
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy | PNAS
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors | Scientific Reports
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies | Nature Immunology
PD-1 Is a Selective Marker of Human Follicular T Cells (A)... | Download Scientific Diagram
Coexpression of PD-1, NFB activation, and proliferation marker in... | Download Scientific Diagram
JCM | Free Full-Text | The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
PD-L1 - Wikipedia
Immune checkpoint blockade in HIV - eBioMedicine
Frontiers | PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation - ScienceDirect
Learning from PD-1 Resistance: New Combination Strategies: Trends in Molecular Medicine
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups | Nature Immunology
Frontiers | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
